Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Cross Below 200 Day Moving Average – Here’s What Happened

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)’s stock price crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $0.19 and traded as low as $0.15. Northwest Biotherapeutics shares last traded at $0.1645, with a volume of 5,902,169 shares trading hands.

Northwest Biotherapeutics Stock Down 10.5%

The company’s 50 day moving average price is $0.16 and its two-hundred day moving average price is $0.19. The firm has a market cap of $272.61 million, a PE ratio of -0.01 and a beta of -0.62.

Northwest Biotherapeutics (OTCMKTS:NWBO) last released its earnings results on Friday, August 14th. The biotechnology company reported ($0.01) EPS for the quarter. The firm had revenue of $0.81 million during the quarter.

Hedge Funds Weigh In On Northwest Biotherapeutics

A hedge fund recently bought a new position in Northwest Biotherapeutics stock. Compass Financial Management LLC bought a new position in shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned about 0.07% of Northwest Biotherapeutics at the end of the most recent reporting period. 0.04% of the stock is owned by institutional investors.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc is a biotechnology company focused on developing personalized immunotherapies for cancer. Its technology uses a patient’s own dendritic cells, which are immune cells that can be prepared to recognize and target that individual’s tumor.

The company’s lead product candidate is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also investigated its platform in other solid tumors, including metastatic cancers, although DCVax-L has been the company’s primary clinical development program.

Northwest Biotherapeutics was founded in 1996 and is based in Bethesda, Maryland.